StockNews.AI
EWTX
StockNews.AI
169 days

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

1. EWTX reported positive Phase 2 results, enhancing its market position. 2. Completion of enrollment in GRAND CANYON boosts prospects for 2025.

Earnings
-6.27%Current Return
VS
-1.83%S&P 500
$26.1703/03 08:19 AM EDTEvent Start
$24.5303/04 03:10 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical trial results historically correlate with stock price increases, as seen with similar companies post FDA trials.

How important is it?

The article highlights significant progress in clinical trials, essential for EWTX's valuation and investor interest.

Why Long Term?

The advancements in their drug pipeline indicate potential future revenue growth and market confidence.

Related Companies

VRTXSGMOAMGN
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2024 and recent business highlights. “Closing out 2024 with positive Phase 2 CANYON results, completing enrollment in GRAND CANYON and advancing CIRRUS-HCM, we are well positioned in 2025 across our muscular dystrophy and cardiovascular portfolio,” said Kevin Koch, Ph.D., President and Chief Exe.

Related News